AstraZeneca’s Bevespi Aerosphere (glycopyrronium/formoterol fumarate) Receives NMPA’s Approval for Patients with COPD

 AstraZeneca’s Bevespi Aerosphere (glycopyrronium/formoterol fumarate) Receives NMPA’s Approval for Patients with COPD

AstraZeneca’s Bevespi Aerosphere (glycopyrronium/formoterol fumarate) Receives NMPA’s Approval for Patients with COPD

Shots:

  • The NMPA’s approval is based on P-III PINNACLE 4 study assessing Bevespi Aerosphere (bid via a pMDI) vs its monotherapy components (glycopyrronium and formoterol fumarate) and PBO in patients with moderate to very severe COPD
  • The P-III PINNACLE 4 study demonstrated improvement in lung function as measured by trough forced expiratory volume in one second (FEV1), published in the International Journal of Chronic Obstructive Pulmonary Disease
  • The approval follows the approval of AstraZeneca’s triple-combination therapy, Breztri Aerosphere (budesonide/glycopyrronium/formoterol fumarate) for the maintenance treatment of COPD in China. Bevespi Aerosphere (FD) is a dual bronchodilator, administered in a pressurized metered-dose inhaler utilizing Aerosphere delivery technology

Click here ­to­ read full press release/ article | Ref: AstraZeneca | Image: DW

Related News: AstraZeneca’s Triple Combination Regimen Receives NMPA’s Approval as the Maintenance Treatment for COPD in China

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post